Cal-Nan Horizon Quest

Cal-Nan (Nanjing) Biopharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. Founded by Dr. Nan-Horng Lin, a former executive at Abbott and AbbVie, the company leverages deep expertise in medicinal chemistry to target key metabolic pathways. Its lead programs include CN-101, a fatty acid synthase (FASN) inhibitor, and CN-102, an acetyl-CoA carboxylase (ACC) inhibitor, both primarily aimed at treating non-alcoholic steatohepatitis (NASH). Cal-Nan operates with a dual presence in Nanjing, China, and California, USA, facilitating cross-border research and development collaborations.